Amgen files marketing applications in the U.S. and Europe for expanded use of Xgeva

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN -0.3%) submits a supplemental Biologics License Application (sBLA) to the FDA and an application for a variation to its MAA to the European Medicines Agency to expand XGEVA's (denosumab) approved use to include the prevention of skeletal-related events (SREs) in multiple myeloma patients.

XGEVA is currently approved for the prevention of SREs in patients with solid tumors.